Skip to main content
. 2021 Apr 23;93(7):4258–4264. doi: 10.1002/jmv.27009

Figure 3.

Figure 3

Schematic describing ExoN proofreading activity and mode of action of inhibitors. (Left Panel) Replication in viruses like Hepatitis C Virus (HCV), with no proofreading mechanism. (Mid panel) Replication in viruses like SARS‐CoV with proofreading Exoribonuclease. (Right panel) It is the same as a mid‐panel but in an ExoN inhibitor 51